Scott Smith
@Acuta Capital Partners, Llc
Latest period2024 - Q3ReportedManaged Assets$123.464MTotal holdings41
Assets growth rate3.99%Assets growth rate (2-Q avg)-9.44%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Acuta Capital Partners, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.
Assets under management
The assets under management (AUM) of Acuta Capital Partners, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 123.464M in assets, with a quarterly growth rate of 3.99% and a 2-quarter average growth rate of -9.44%. The portfolio is managed by Scott Smith, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ASNDAscendis Pharma A S
| 2.54% | $3.136M 21,000 shares@ $149.31 avg price | New Position |
CMPSCompass Pathways Plc
| 1.98% | $2.435M 386,500 shares@ $6.3 avg price | New Position |
SLRNAcelyrin Inc
| 1.46% | $1.795M 364,000 shares@ $4.93 avg price | New Position |
EWTXEdgewise Therapeutics Inc
| 1.37% | $1.681M 63,000 shares@ $26.69 avg price | New Position |
GILDGilead Sciences Inc
| 1.33% | $1.635M 19,500 shares@ $83.84 avg price | New Position |
RAREUltragenyx Pharmaceutical Inc
| 1.13% | $1.394M 25,100 shares@ $55.55 avg price | New Position |
UNCYUnicycive Therapeutics Inc
| 0.66% | $807,315 1.979M shares@ $0.41 avg price | New Position |
LQDALiquidia Corporation
| 0.6% | $735,000 73,500 shares@ $10.0 avg price | New Position |
VERVVerve Therapeutics Inc
| 0.58% | $707,124 146,100 shares@ $4.84 avg price | New Position |
GERNGeron Corp
| 0.57% | $703,246 154,900 shares@ $4.54 avg price | New Position |